Main public logs
Jump to navigation
Jump to search
Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).
- 00:22, 6 February 2024 Edzelco talk contribs uploaded File:Ganaloxone bottle suspension label 50mg.png
- 00:21, 6 February 2024 Edzelco talk contribs created page File:Ganaloxone structure.png
- 00:21, 6 February 2024 Edzelco talk contribs uploaded File:Ganaloxone structure.png
- 15:47, 2 February 2024 Edzelco talk contribs created page Pacritinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Pacritinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L (1) |adverseReactions=diarrhea, thrombocytopenia, nausea, anemia, and peripheral edema |fdaLIADAdult=The recommended dosage of VONJO is 200 mg orally twi...")
- 15:47, 2 February 2024 Edzelco talk contribs created page File:Pacritinib Bottle Label.png
- 15:47, 2 February 2024 Edzelco talk contribs uploaded File:Pacritinib Bottle Label.png
- 15:47, 2 February 2024 Edzelco talk contribs created page File:Pacritinib Carton Label.png
- 15:47, 2 February 2024 Edzelco talk contribs uploaded File:Pacritinib Carton Label.png
- 15:47, 2 February 2024 Edzelco talk contribs created page File:Pacritinib supply.png
- 15:47, 2 February 2024 Edzelco talk contribs uploaded File:Pacritinib supply.png
- 15:47, 2 February 2024 Edzelco talk contribs created page File:Pacritinib structure.png
- 15:47, 2 February 2024 Edzelco talk contribs uploaded File:Pacritinib structure.png
- 16:13, 1 February 2024 Edzelco talk contribs created page Mitapivat (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=mitapivat |aOrAn=a |drugClass=pyruvate kinase activator |indicationType=treatment |indication=hemolytic anemia in adults with pyruvate kinase (PK) deficiency |adverseReactions=estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia |fdaLIADAdult=PYRUKYND is taken with or without food and swallowed whole. Do not split, crush, chew,...")
- 16:08, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 5mg.png
- 16:08, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 5mg.png
- 16:08, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 5mg tablet blister pack.png
- 16:08, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 5mg tablet blister pack.png
- 16:07, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 20mg.png
- 16:07, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 20mg.png
- 16:07, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 20mg tablet blister pack.png
- 16:07, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 20mg tablet blister pack.png
- 16:07, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 50mg.png
- 16:07, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 50mg.png
- 16:07, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 50mg tablet blister pack.png
- 16:07, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 50mg tablet blister pack.png
- 16:06, 1 February 2024 Edzelco talk contribs created page File:Mitapivat structure.png
- 16:06, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat structure.png
- 16:06, 1 February 2024 Edzelco talk contribs created page File:Mitapivat supply.png
- 16:06, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat supply.png
- 15:46, 1 February 2024 Edzelco talk contribs created page Sutimlimab-jome (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Sutimlimab-jome |aOrAn=a |drugClass=classical complement inhibitor |indicationType=treatment |indication=hemolysis in adults with cold agglutinin disease (CAD) |adverseReactions=in the CADENZA study (Part A) (incidence ≥18%) are rhinitis, headache, hypertension, acrocyanosis, and Raynaud's phenomenon. The most common adverse reactions in the CARDINAL study (incidence ≥...")
- 15:44, 1 February 2024 Edzelco talk contribs created page File:Sutimlimab-jome packaging.png
- 15:44, 1 February 2024 Edzelco talk contribs uploaded File:Sutimlimab-jome packaging.png
- 15:31, 1 February 2024 Edzelco talk contribs created page Faricimab-svoa (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Faricimab-svoa |aOrAn=a |drugClass=vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor |indicationType=treatment |indication=patients with neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO) |adverseReactions=cataract (15%) and [[conjunctival hemorrhage]...")
- 14:59, 1 February 2024 Edzelco talk contribs created page Tebentafusp-tebn (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Tebentafusp-tebn |aOrAn=a |drugClass=bispecific gp100 peptide-HLA-directed CD3 T cell engager |indicationType=treatment |indication=HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma |hasBlackBoxWarning=Yes |adverseReactions=cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache and vomiting. The most...")
- 01:46, 1 February 2024 Edzelco talk contribs created page File:Abrocitinib 200mg.png
- 01:46, 1 February 2024 Edzelco talk contribs uploaded File:Abrocitinib 200mg.png
- 01:46, 1 February 2024 Edzelco talk contribs created page File:Abrocitinib 100mg.png
- 01:46, 1 February 2024 Edzelco talk contribs uploaded File:Abrocitinib 100mg.png
- 01:43, 1 February 2024 Edzelco talk contribs created page File:Abrocitinib 50mg.png
- 01:43, 1 February 2024 Edzelco talk contribs uploaded File:Abrocitinib 50mg.png
- 01:39, 1 February 2024 Edzelco talk contribs created page File:Abrocitinib supply.png
- 01:39, 1 February 2024 Edzelco talk contribs uploaded File:Abrocitinib supply.png
- 01:32, 1 February 2024 Edzelco talk contribs created page File:Abrocitinib.png
- 01:32, 1 February 2024 Edzelco talk contribs uploaded File:Abrocitinib.png
- 01:31, 1 February 2024 Edzelco talk contribs created page Abrocitinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |indicationType=treatment |indication=adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOS...")
- 21:17, 31 January 2024 Edzelco talk contribs created page Daridorexant (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=daridorexant |aOrAn=an |drugClass=orexin receptor antagonist |indicationType=treatment |indication=adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance |adverseReactions=Common adverse reactions (reported in ≥ 5% of patients treated with QUVIVIQ and at an incidence ≥ than placebo) include headache and somnolence or fatigue...")
- 21:15, 31 January 2024 Edzelco talk contribs created page File:Clinical Studies 3.png
- 21:15, 31 January 2024 Edzelco talk contribs uploaded File:Clinical Studies 3.png
- 21:15, 31 January 2024 Edzelco talk contribs created page File:Clinical Studies 2.png
- 21:15, 31 January 2024 Edzelco talk contribs uploaded File:Clinical Studies 2.png
